Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented during the European Haematology Association's annual congress in Barcelona, Spain.

The study of 459 patients 65 years or older evaluated patients receiving lenalidomide in combination with melphalan and prednisone, followed by lenalidomide alone (MPR-R)>

Median PFS of the MPR-R arm has yet to be reached, while the MP arm had a median PFS of 13 months (p<0.001). Patients treated with MPR-R had a 58% reduction in the risk of disease progression compared to MP, an improvement over the reduction in risk of disease progression reported at the first interim analysis in December 2009. At the time of the second analysis, it was estimated that 55% of all patients receiving MPR-R would remain progression free after two years compared to only 16% of patients receiving MP.

In the safety population (the patients who received at least one dose of therapy on study), the most common grade 3 or 4 hematological adverse events included neutropenia (71%, MPR-R vs. 30%, MP), thrombocytopenia (39%, MPR-R vs. 14%, MP) and febrile neutropenia (7%, vs. 0%, MP). Grade 3 or 4 non-hematological adverse events included fatigue (6%, MPR-R vs. 3%, MP), deep-vein thrombosis/pulmonary embolism (4%, MPR-R vs. 1%, MP), and rash (5%, MPR-R vs. 1%, MP). No grade 3 or 4 peripheral neuropathy was experienced by patients in this study.

These data are from an investigational study. REVLIMID is not approved as an initial treatment for patients with multiple myeloma.


Celgene International Sàrl


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions